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With multidrug-resistant cases of tuberculosis in-
creasing globally, better antibiotic drugs and novel
drug targets are becoming an urgent need. Tradi-
tional b-lactam antibiotics that inhibit D,D-trans-
peptidases are not effective against mycobacteria,
in part because mycobacteria rely mostly on L,D-
transpeptidases for biosynthesis and maintenance
of their peptidoglycan layer. This reliance plays a
major role in drug resistance and persistence of
Mycobacterium tuberculosis (Mtb) infections. The
crystal structure at 1.7 A˚ resolution of the Mtb
L,D-transpeptidase LdtMt2 containing a bound pep-
tidoglycan fragment, reported here, provides infor-
mation about catalytic site organization as well as
substrate recognition by the enzyme. Based on our
structural, kinetic, and calorimetric data, we propose
a catalytic mechanism for LdtMt2 in which both
acyl-acceptor and acyl-donor substrates reach the
catalytic site from the same, rather than different,
entrances. Together, this information provides vital
insights to facilitate development of drugs targeting
this validated yet unexploited enzyme.
INTRODUCTION
Multidrug-resistant (MDR) and extensively drug-resistant (XDR)
strains of Mycobacterium tuberculosis (Mtb) are emerging at
alarming rates (Fauci, 2008). A possible reason for this is poor
patient compliance with existing treatments, which require
multiple drugs to be taken daily for at least 6 months (Medical
Section of the American Lung Association, 1997) to eliminate
the resilient 1% of bacilli, commonly known as persisters (Jin-
dani et al., 2003; Lewis, 2007). Any strategy aimed at shortening
duration of tuberculosis therapy must be effective in eliminating
the persisters.Mtb persists in the lungs of infected individuals in
a slow-growing, nonreplicating dormant state in which the
bacillus is resistant to the host immune response and is tran-Structure 20, 2103–21siently tolerant of antibiotics (Betts et al., 2002; Bishai, 2000).
Mtb persisters extracted from lung lesions show morphological
changes similar to those observed in bacilli that are subject to
nutrient starvation or anaerobic stress (Betts et al., 2002). These
changes involve, among other physiologic alterations, the re-
modeling of the Mtb peptidoglycan layer (Lavollay et al., 2008),
a vital layer consisting of an elaborate network of peptidoglycan
chains with crosslinked peptide stems.
Formation of the most common type of crosslink, the (D,D)
4/3 linkage (Figure 1A, top), is catalyzed by the D,D-transpep-
tidase activity of enzymes commonly referred to as penicillin
binding proteins. These enzymes catalyze the transfer of the
peptide bond between the fourth residue (D chiral center) and
the fifth residue of a pentapeptide donor stem to a side-chain
amide group (also a D chiral center) at the third residue of an
adjacent acceptor stem (usually a diamino acid). A second
type of crosslink, the (L,D) 3/3 linkage (Figure 1A, bottom), is
catalyzed by L,D-transpeptidases such as the one studied
here. These enzymes transfer the peptide bond between the
third residue (L chiral center) of a tetrapeptide donor stem
to the side-chain amide group of the third residue (D chiral
center) of an adjacent acceptor stem. In both types of trans-
peptidases, the catalysis proceeds by a two-step mechanism:
acylation of the enzyme by the penultimate peptide of the
donor stem with the release of the stem C-terminal residue,
followed by deacylation of this acyl-enzyme intermediate by an
acceptor stem.
The 3/3 linkages were first identified in 1974 by Wietzerbin
et al. in the peptidoglycan of mycobacteria (Wietzerbin et al.,
1974), but their significance and biosynthetic pathway remained
unknown until recently, when their predominance in Mtb was
demonstrated, and LdtMt1 (or MT0125, the product of gene
Rv0116c) was identified as an L,D-transpeptidase that generates
3/3 linkages (Lavollay et al., 2008). Frequently associated
with virulence and b-lactam resistance, predominance of 3/3
linkage has been observed in spontaneous mutation of Entero-
coccus faecium (Mainardi et al., 2005), in other mycobacteria
M. abscessus (Lavollay et al., 2011), and in the spore-forming
bacteria Clostridium difficile (Peltier et al., 2011).
Recently, another 3/3 L,D-transpeptidase, LdtMt2 (MT2594,
the product of gene Rv2518c), was characterized inMtb (Gupta
et al., 2010). AnMtb strain lacking LdtMt2 loses virulence and has15, December 5, 2012 ª2012 Elsevier Ltd All rights reserved 2103
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Figure 1. Peptidoglycan Linkages and
Structure of LdtMt2
(A) 4/3 and 3/3 linkages. The C-terminal resi-
dues from the g-D-Glu of donor and acceptor
peptidoglycan stems are depicted in different
colors: g-D-Glu (red), m-A2pm (blue), and D-Ala
(cyan). Residue numbers of the acceptor stem are
primed.
(B) Cartoon representation of the overall structure
of ex-LdtMt2 with elements of secondary structure
labeled. Two pink arrows mark the beginning and
end of the CTSD. The peptidoglycan fragment
bound to the active site is also shown in a stick
representation. N-term, N terminal; C-term, C
terminal.
(C and D) Views of the solvent-accessible surface
of ex-LdtMt2 colored by electrostatic surface
potential (from blue positive to red negative). (C)
Side view with the same orientation as (B). The
stick representation of peptidoglycan fragment
bound to the active site is shown. Oxygen atoms
are colored in red, nitrogen atoms in blue, sulfur
atoms in yellow, and carbon atoms in green. (D)
Top view of the outer cavity (rotated 90 around a
horizontal axis from B). The surface was rendered
transparent and the peptidoglycan fragment
removed to show residues and secondary struc-
ture elements lining the outer cavity.
See also Figure S1.
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Structure of Mtb LdtMt2attenuated growth during the chronic phase of the disease
(Gupta et al., 2010). In addition, this strain is more susceptible
to the therapeutic combination of amoxicillin and clavulanic
acid, suggesting that the (3/3) L,D-transpeptidase activity is
a major contributor to b-lactam resistance. It was also shown
that a vaccine utilizing an M. bovis BCG strain that overex-
presses L,D-transpeptidases has enhanced protective efficacy
against Mtb persisters (Nolan and Lamichhane, 2010), suggest-
ing that the higher degree of 3/3 linkages resulting from the
overexpression of the enzyme better represents the peptido-
glycan layer of Mtb persisters.
Despite the obvious significance of L,D-transpeptidases in
Mtb growth and virulence, to our knowledge, no structural or
binding information exists for the five members of this class of
Mtb enzymes identified to date (Gupta et al., 2010). Here, we
present the characterization of the extramembrane portion of
LdtMt2 (ex-LdtMt2), including the determination of its structure
at 1.7 A˚ resolution. Ex-LdtMt2 is composed of two domains:
an N-terminal immunoglobulin-like domain, and a C-terminal
catalytic ErfK/YbiS/YhnG domain (Pfam accession number
PF03734). Based on this structure, comparative modeling of
the identified Mtb homologs indicates that the N-terminal
domain fold and the enzyme’s overall conformation distinguish2104 Structure 20, 2103–2115, December 5, 2012 ª2012 Elsevier Ltd All rights reservedthis group from other structurally charac-
terized ErfK/YbiS/YhnG domain-contain-
ing proteins such as Bacillus subtilis
ykuD (Bielnicki et al., 2006) andE. faecium
L,D-transpeptidase Ldtfm (Biarrotte-Sorin
et al., 2006).
The catalytic site of LdtMt2, located at
the entrance of a narrow tunnel connect-ing two cavities that are open to the solvent, is similar to that
observed in Ldtfm (Biarrotte-Sorin et al., 2006). Unexpectedly,
the crystal structure shows the presence of a fragment of the
peptidoglycan of the expression host (E. coli) in the catalytic
site of the enzyme. Until now, to our knowledge, no related
L,D-transpeptidase has been structurally characterized with
a bound peptidoglycan fragment. LdtMt2 recognizes the peptido-
glycan (acyl-donor-like) using residues located in both cavities,
including the catalytic residues Cys354 and His336. The
observed mode of binding of this short peptidoglycan fragment
led us to propose a catalytic mechanism for these transpepti-
dases that differs from that previously posited by Biarrotte-Sorin
et al. (2006).
Kinetic measurements show that LdtMt2 has residual hydro-
lase activity toward certain b-lactams. Isothermal titration calo-
rimetry (ITC) experiments show that the carbapenems (Bonfiglio
et al., 2002), imipenem and meropenem, bind only the catalyti-
cally active enzyme, and they do so with apparent submicromo-
lar affinities. The structural, biochemical, and thermodynamic
data presented here provide vital information about the interac-
tions of the enzyme with its substrates and inhibitors that will
help advance this unexploited enzyme into a target for the design
of novel compounds for the treatment of Mtb infections.
Table 1. Data Collection Statistics of the PIP Complex Used to Refine the Structure and of the SeMet Crystal Used for Phase
Determination
Crystal PIP (Refinement) SeMet (Phase Determination)
Space group I212121
Wavelength CuKa 0.96785 A˚ 0.97907 A˚ 0.97939 A˚
Cell dimensions
a, b, c (A˚) 119.1, 120.8, 122.8 118.3, 121.1, 122.5
a, b, g () 90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0
Resolution range (last shell) (A˚) 85.7–1.72 (1.89–1.72) 50.0–2.78 (2.83–2.78) 50.0–2.45 (2.49–2.45) 50.0–2.54 (2.58–2.54)
Rsym 0.051 (0.310) 0.099 (0.683) 0.095 (0.478) 0.087 (0.615)
I/s(I) 29.2 (2.5) 18.1 (1.7) 22.6 (2.9) 20.9 (2.0)
Completeness (%) 99.6 (99.6) 97.6 (83.0) 97.8 (85.4) 96.9 (80.5)
Redundancy 3.5 (2.3) 9.4 (6.6) 9.4 (6.6) 9.4 (6.0)
Refinement
Resolution (A˚) 50–1.72 (1.765–172)
No. of reflections 84,134 (287)
Rwork/Rfree 0.19/0.23 (0.3/0.32)
No. of atoms
Protein 4,075
Ligands/ions 111
Peptoglycans 44
PIP adducts 67
Waters 471
B factors (A˚2)
Protein 36.9
Ligands/ions 67.1
Waters 49.7
Rmsds
Bond lengths (A˚) 0.009
Bond angles () 1.297
Ramachandran
Most favorable region (%) 98.5
Allowed regions (%) 1.5
Outliers (%) 0
See also Table S1 for statistics of other crystal forms.
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Structure of Mtb LdtMt2RESULTS
Ex-LdtMt2 Crystal Structure
The extramembrane portion of the L,D-transpeptidase fromMtb,
LdtMt2 (ex-LdtMt2, residues 120–408), was cloned and expressed
in E. coli. A crystal of a seleno-methionine (SeMet) derivative of
ex-LdtMt2 was used to determine the structure using multiple
anomalous dispersion (MAD) methods. The structure was
refined to a final Rwork of 0.19 and an Rfree of 0.23 using diffrac-
tion data collected from a di-m-Iodo-bis[ethylenediamine]-di-Pt
[II] (PIP) derivative crystal (Figure 1B; Table 1; see Figure S1 avail-
able online), which had the best diffraction among all the crystals
tested (1.7 A˚ resolution). Crystals of ex-LdtMt2 belong to the
orthorhombic space group I212121 and contain two monomers
(A and B) in the asymmetric unit. These two molecules do not
correspond to a physiological dimer because ex-LdtMt2 behaves
as a monomer in solution, as determined by size exclusion chro-Structure 20, 2103–21matography (data not shown). In addition, areas buried by the
two possible dimers in the crystal asymmetric unit, 810 and
1,360 A˚2, are not consistent with a dimer stable in solution (Kris-
sinel, 2011).
A portion of the N-terminal region of ex-LdtMt2, spanning resi-
dues 122–132, is observed only in monomer B with low occu-
pancy (50%) and disconnected from the bulk of the fold. Amino
acids from 150 to 407 are observed in both monomers of the
crystal asymmetric unit with an rmsd of 0.31 A˚ between the
aligned 258 Ca atoms of monomers A and B. Each monomer
consists of two globular domains: an N-terminal domain (resi-
dues 150–250) folded as an antiparallel b barrel resembling an
immunoglobulin domain (IgD) (Amzel and Poljak, 1979); and
aC-terminal catalytic domain (CD; residues 254–407), consisting
of a b sandwich with two mixed b sheets characteristic of the
ErfK/YbiS/YhnG fold (Bielnicki et al., 2006). A short linker (resi-
dues 251–253) joins the two domains (Figure 1B). A small15, December 5, 2012 ª2012 Elsevier Ltd All rights reserved 2105
Figure 2. Sequence Alignment of LdtMt2, the
L,D-Transpeptidase of E. faecium, and
Other Mtb LdtMt2 Homologs
Top view shows domain distribution of LdtMt2. The
ex-LdtMt2 protein construct used in this work is
indicated by a dashed red box. Bottom view
presents sequence alignment among aa 138–408
of LdtMt2, LdtMT1, Ldtfm, and other LdtMt2 homo-
logs in Mtb. The observed secondary structure is
indicated above the corresponding residues.
Identical residues are white with red background;
regions scoring higher than 70% using a Risler’s
similarity scoring matrix (Risler et al., 1988) are
boxed with red letters. Residues involved in
binding and catalysis are labeled: the conserved
motif is indicated with green marks and the rest
with pink marks. Stars label main catalytic resi-
dues, and ovals label substrate recognition resi-
dues. The figure was made using the web server
ESPript (http://espript.ibcp.fr/ESPript/ESPript/).
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Structure of Mtb LdtMt2C-terminal subdomain (CTSD; residues 379–407) extends the
ErfK/YbiS/YhnG fold. In this subdomain, Trp394 and two Trp
residues of the C-terminal helix a3 (398 and 401) make
a zipper-like interaction with the IgDN-terminal domain that fixes
the relative orientation of the two domains.
The N-terminal domain has characteristics not commonly
found in Ig domains (Amzel and Poljak, 1979): the interstrand
loops are unusually long, including a three-turn helix (a1) in the
loop connecting strands b3 and b4. In the refined structure, PIP
was found to have reacted with solvent-exposed Nd atoms of
histidine residues and with sulfur atoms of methionine residues
(His214 in monomer A, and Met153, Met157, Met237, and
His347 in both monomers) to form five (four in monomer B)
iodo-Pt(II) ethylenediamine adducts (Figure S1) (O’Halloran
et al., 1987).
Active Site
A two-step enzymatic mechanism resembling that of D,D-trans-
peptidases was proposed for the ErfK/YbiS/YhnG-fold family of
transpeptidases, except that the catalytic serine of D,D-trans-
peptidases is replaced by an absolutely conserved cysteine
residue (Mainardi et al., 2007). A highly conserved sequence
motif of this group of L,D-transpeptidases, HXX14–17[S/T]HGChN
(where ‘‘h’’ stands for a hydrophobic residue, Figure 2), contains2106 Structure 20, 2103–2115, December 5, 2012 ª2012 Elsevier Ltd All rights reservedthree residues (underlined letters) analo-
gous to the catalytic triad of cysteine
proteases: a cysteine, a histidine, and
a third residue that accept a hydrogen
(H) bond from the histidine stabilizing the
competent imidazole tautomer (Bielnicki
et al., 2006; Dodson and Wlodawer,
1998).
In ex-LdtMt2, those catalytic residues,
His336, Ser337, and Cys354, reside
under a flap formed by a long insert (resi-
dues 299–323) that is not part of the
canonical ErfK/YbiS/YhnG fold (Bielnicki
et al., 2006). This insert, strand b15,loop LF, and strand b16, folds over the b sheet formed by
strands b17, b18, and b19 (residues 324–357). The closed flap
creates two large cavities (vestibules) connected by a narrow
tunnel. These cavities are open to solvent: one at the end of
the molecule, and the other at the interface between the CD
and IgD (Figure 1C, outer and inner cavities, respectively).
Strand b16 (residues 318–323), the C-terminal end of b18 (resi-
dues 336 and 337), the loop Lc (residues 338–352), and the
strand b19 (residues 353–357) line the outer cavity (Figure 1D).
The residues of the conserved motif (Figure 2) are readily acces-
sible through the outer cavity, with the catalytic residues
located deep within it. With the exceptions of His336 and
Ser337 (both in b18), the conserved motifs extend through the
end of loop Lc and strand b19. Ser351, His352, and Gly353
are located in loop Lc, whereas Cys354 and Asn356 in strand
b19 (Figure 1D). Other highly conserved residues in similar
sequences of Gram-positive bacteria, Tyr318 and Gly332 in
LdtMt2 (Figure 2), are located at the inner cavity. Tyr318 and
Met303 line the internal side of the flap and, together with
Cys354, form the walls of the narrow tunnel. His336 and
His352 flank the tunnel at the outer cavity (Figure 1D). The
carbonyl group of Ser337 accepts an H bond from the Nd of
His336 (2.8 A˚). This H bond stabilizes the tautomer of His336
protonated at Nd.
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Figure 3. Comparative Modeling of Mtb Homologs
(A) Overlay of Ca trace of the modeled structures of theMtb homologs with the
crystal structure of ex-LdtMt2 (green).
(B) Overlay of the modeled catalytic sites. Residues participating in the inter-
actions with the substrate are displayed. Carbon atoms are colored with the
same color as the corresponding Ca trace: green, LdtMt2; yellow, MT1477;
pink, MT0501; magenta, LdtMt1; and cyan, MT0202. Noncarbon atoms are
colored as in Figure 1.
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Structure of Mtb LdtMt2Comparison of LdtMt2 with Mtb Paralogs
The presence of five genes in Mtb that code for proteins with
potential L,D-transpeptidase activity has been reported (Gupta
et al., 2010). Of these proteins, only LdtMt1 (Lavollay et al.,
2008) and LdtMt2 (Gupta et al., 2010) have been shown to be
functional L,D-transpeptidases. The multiple alignment of LdtMt2
with the other Mtb proteins shows pairwise sequence identities
ranging from 33% to 45% (Figure 2), suggesting a high structural
similarity of these proteins to ex-LdtMt2. Comparative models of
these proteins were built using LdtMt2 as a template (Figure 3).
The overall fold of the IgD is conserved among these proteins.
Three homologs, MT0202 (also know as Rv0192, 45% identity
with LdtMt2), LdtMt1 (36%), and MT1477 (Rv1433, 33%), have
a short loop connecting strands b7 and b10 and lack strands b8
and b9 of the ex-LdtMt2 IgD (Figures 2 and 3A). The bulk of the
CD has little variation among homologs: MT0501 (Rv0483,
34%) has the shortest loop LF among the five proteins, and
MT1477 shows an 18-residue insertion after b12. The CTSDs of
these homologs, however, show significant differences with
LdtMt2. The only exception is MT0501, which contains a CTSD
of the same size and features as LdtMt2. MT1477 and LdtMt1
completely lack this subdomain, and MT0202 has a significantly
shortened version. Most of the motif residues (Figure 2) are
conserved in these proteins, with the exception of the replace-
ment of His 352 (LdtMt2 numbering; Figure 2) by an asparagineStructure 20, 2103–21in MT0501. In the neighborhood of the active site, a methionine
in MT0501 replaces the highly conserved Trp340 of LdtMt2
(Figures 2 and 3B).
Peptidoglycan Fragment
Electron density not belonging to protein residues was present in
the catalytic site of the SeMet and the PIP derivative crystals.
This density, longer and more branched than either a succinic
acid or a PEGmolecule from the crystallization media, was inter-
preted as belonging to a dipeptide fragment of a muropeptide
stem, probably a fragment of the E. coli peptidoglycan bound
from the lysis supernatant and carried through the purification
process. Ex-LdtMt2 probably recognizes common features
between its physiological substrate and a muropeptide of
E. coli. The peptidoglycan of Mtb contains muropeptides
composed of an N-acetylglucosamine joined by a b (1-4)-glyco-
sidic bond to an N-acetylmuramic acid decorated with four or
five amino acid-long peptide stems (NAcGlc-b[1,4]-MurNAc-L-
Ala1-g-D-GLu2-m-A2pm-NH2
3-D-Ala4 -[D-Alanyl5]) (Barreteau
et al., 2008). The electron density, 14 A˚ in length, broadens at
three places that correspond to carboxylates of the peptido-
glycan (Figures 4A and S2). The broadest section, at the center
of the catalytic site, is connected by narrow zigzag densities to
two broad densities located at the tunnel entrances across
from the active site tunnel. Based on the separation and size of
these features, a g-D-Glu-m-A2pm dipeptide was built into this
electron density (Figure 4A), with the terminal peptide L chiral
center placed near the catalytic His336 and the D chiral center
in the inner cavity of the tunnel, H bonded by Tyr318 and main-
chain carboxyl of Gly332. The SH group of Cys354 is 4.6 A˚
from the carboxylate group of the dipeptide A2pm moiety (Fig-
ure 4A). This carboxylate makes H bonds with the Nε of His336
and the Nd1 of Asn356, both residues of the conserved motif
(Figure 2). The g-D-Glu-m-A2pm dipeptide may correspond to
the second and third peptide moieties of a peptidoglycan stem.
Chemical Modification of Cys354 in the Absence
of Ligand
During the structural analysis, several of the structures of
different native crystal forms showed modifications of Cys354
by buffer components or molecular oxygen (Figures 4B and
4C; Table S1). When b-mercaptoethanol (BME) is present, a
disulfide bridge is formed between the Sg of Cys354 and BME
(Figure 4B). The rest of the molecule remains unperturbed (rms
0.17 A˚ for 524 Cas of the crystal asymmetric unit). In protein
crystals without endogenous ligand (obtained by purifying the
protein under denaturing conditions; see Supplemental Experi-
mental Procedures), Cys354 is in its sulfenic acid form (Fig-
ure 4C). The rest of the structure, including the active site,
does not show significant changes (rms 0.23 A˚ for 524 Cas of
the crystal asymmetric unit).
Binding of Carbapenems to Wild-type and C354A LdtMt2
Two classes of antibiotics inhibit polymerization of the cell wall
peptidoglycan: b-lactams and glycopeptides. Carbapenems
are a subfamily of b-lactam antibiotics that irreversibly inhibit
classical D,D-transpeptidases (Bonfiglio et al., 2002). Three
carbapenems—imipenem (Figure 5A), meropenem (Figure 5B),
and ertapenem—have been shown to also be active against15, December 5, 2012 ª2012 Elsevier Ltd All rights reserved 2107
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Figure 4. Electron Densities at the Catalytic
Site of LdtMt2
(A) Final refinement 2DFo mFc map of the coc-
rystallized peptidoglycan fragment contoured at
0.5 s (see below) around the g-D-Glu-m-A2pm
fragment at the active site of ex-LdtMt2. The fitted
fragment, binding residues, and the catalytic
cysteine are shown. H bond interactions with
conserved residues are shown with pink dashed
lines. Because the two binding sites in the non-
crystallographic dimer occur side-by-side, over-
lapping density for two equivalent peptidoglycan
fragments was observed. The density was in-
terpreted as two equivalent ligands related by the
noncrystallographic 2-fold and refined as alterna-
tive orientations with occupancy of 0.5.
(B and C) Modifications of Cys354 observed in
native forms. (B) BME covalently bound to Cys354
(2.0 A˚ bond distance). The rmsd between this
structure (native form) and the refined (PIP deriv-
ative) is 0.176 A˚ for 520 Ca atoms of the asym-
metric unit. Final refinement 2DFo mFc electron
density map contoured at 1 s around Cys354. (C)
Oxidized Cys354 (sulphenic acid form). Atoms are
colored as in Figure 1.
See Table S1 for structure determination statistics
of the BME-adduct and oxidized forms. See also
Figure S2 for a stereo view of an omit map.
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Structure of Mtb LdtMt2L,D-transpeptidases. Adducts of these carbapenems to Ldtfm
(Mainardi et al., 2007), LdtMt1 (Lavollay et al., 2008), and LdtMt2
(Gupta et al., 2010) were identified using mass spectrometry.
To characterize direct binding of imipenem andmeropenem to
LdtMt2 in the absence of enzymatic activity, we performed ITC
using a catalytically inactive mutant C354A. Surprisingly, no
heat of complex formation was observed with the mutant protein
with either imipenem (Figure 6A) or meropenem (data not shown)
at ligand concentrations up to the millimolar range. In contrast,
ITC experiments with the wild-type ex-LdtMt2 show strong
binding of both carbapenems to the enzyme (Figures 5C and 5D).
Lack of binding by the C354A mutant is not due to a large
structural change: the crystal structure of the mutant (Figure 6B;
Table S1) shows no significant changes with respect to the wild-
type (rmsd of 0.26 A˚ for 516 Ca atoms of the asymmetric unit).
The absence of a thiol group at the residue 354 slightly widens
the narrowest section of the tunnel, producing only minor distur-
bances in other binding site residues, not enough change to
explain the lack of binding (Figure 6B).
Imipenem has approximately 17 times higher affinity for the
enzyme than meropenem, which have been shown effective in
combination with clavulanate for inhibit Mtb BlaC (Hugonnet
et al., 2009) (Figures 5C and 5D). Although binding of imipenem2108 Structure 20, 2103–2115, December 5, 2012 ª2012 Elsevier Ltd All rights reservedto LdtMt2 is exothermic, the same reaction
with meropenem is endothermic (Figures
5C and 5D). The meropenem-positive DS
of binding, a consequence of its large
hydrophobic surface area, partially com-
pensates for the unfavorable enthalpic
contribution.
In addition to meropenem and imipe-
nem, a potent b-lactamase inhibitor, clav-ulanic acid, was tested as a ligand of ex-LdtMt2. ITC experiments
did not detect binding by this compound to wild-type ex-LdtMt2,
even at concentrations in the millimolar range (data not shown).
The BME disulfide adduct (Figure 4B) observed when protein
samples are treated with BME interferes with imipenem and
meropenem binding: the KD of these compounds increases an
order of magnitude (data not shown).
b-Lactamase Activity of ex- LdtMt2
The kinetics of opening the lactam ring of imipenem by ex-LdtMt2
displays the expected irreversible inhibitor characteristics (Fig-
ures 7A and 7B). The enzymatic reaction stops after one turn-
over. The ratio of the total amount of imipenem rings opened
to the amount of enzyme added is close to one (0.96 ± 0.07,
Figure 7B).
To further characterize the enzyme, the b-lactamase activity of
ex-LdtMt2 was measured using the chromogenic substrate nitro-
cefin as a reporter (O’Callaghan et al., 1972). A low b-lactamase
activity was observed, with a KM of 16 mM and a kcat of 0.01 s
1
(Figure 7C; Table S2). The pH profile of the reaction shows
a maximum catalytic rate at pH 7.8 (Figure 7D; Table S3). The
enzymatic reaction shows the biphasic kinetics observed before
in b-lactamases (Figures 7E and 7F). An initial burst of activity
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Figure 5. ITC Experiments
The chemical structures of (A) imipenem ((5R,
6S)-6-[(1R)-1-hydroxymethyl]-3-({2-[iminomethyl)
amino]ethyl}thio)-7-oxo-1 azabicyclo[3.2.0]hept-
2-ene-2-carboxylic acid) and (B) meropenem
(3-[5-(dimethylcarbamoyl) pyrrolidin-2-yl] sulfanyl-
6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo
[3.2.0]-hept-2-ene-2-carboxylic acid) are shown.
Titrations of (C) imipenem and (D) meropenem
binding to LdtMt2 are shown in the upper portion of
the panels. The lower portion of the panel displays
plots of the total heat released as a function of the
molar ratio between each carbapenem and LdtMt2.
The solid line represents the nonlinear least-
squares fit of the data using a single-site binding
model. Thermodynamic parameters of binding to
ex-LdtMt2—KD, DH, and DS—are tabulated at the
bottom of the figure. Conc., concentration.
Structure
Structure of Mtb LdtMt2(Figure 7E) is followed by a linear slower rate (kdeacylation,
33.4 nM/min; Figure 7F), characteristic of a bifurcated kinetic
path consistent with the formation of an alternative, more labile,
acyl-enzyme intermediate species (Monks and Waley, 1988).
Two pieces of evidence reduce the possibility that contamina-
tion with b-lactamases from the bacterial expression host is the
source of the weak activity observed. First, the C354A mutant of
ex-LdtMt2 expressed and purified the same way as the wild-type
shows no detectable b-lactamase activity (data not shown).
Second, no inhibition of ex-LdtMt2 b-lactamase activity was
detected with clavulanic acid (data not shown), which at the
concentrations tested (tens of millimolars), should have inhibited
most known bacterial b-lactamases.
DISCUSSION
The degree of crosslinking and proportion of each type of linkage
in the peptidoglycan layer vary among different bacterial species
as well as during different growth phases. For example, the
degree of crosslinking of the E. coli peptidoglycan is approxi-Structure 20, 2103–2115, December 5, 2012 ªmately 50%, with 4/3 linkages account-
ing for 95% (90% in stationary phase) of
the linkages (Vollmer and Ho¨ltje, 2004).
In contrast, the degree of crosslinking of
the Mycobacterium spp peptidoglycan
is as high as 80%, with 3/3 linkages
comprising 70% (80% in stationary
phase) of total linkages (Matsuhashi,
1966). This high frequency of 3/3 link-
ages in mycobacteria contrasts sharply
with the low level commonly observed
in most other bacteria. For example, in
E. coli and E. faecium, 3/3 linkages
represent only a relatively small fraction
of the total: 5% during growth phases,
and 10% in stationary phase (Tuomanen
and Cozens, 1987).
During the stationary phase of growth,
formation of new 4/3 linkages is
impaired because the mature peptido-glycan layer has few pentapeptide stems, the required sub-
strates of D,D-transpeptidases, and the de novo synthesis of
precursors is significantly reduced (Goffin and Ghuysen, 2002).
In contrast, L,D-transpeptidases could still crosslink the avail-
able tetrapeptide donors.
Expression of the Mtb L,D transpeptidase LdtMt1 is upregu-
lated in the transcriptome of laboratory models of persisters
(Betts et al., 2002; Keren et al., 2011) and shows a 17-fold
increase during the activation of the dormancy regulon of Mtb
(Lavollay et al., 2008). Interestingly, in all growth phases of
Mtb, expression of LdtMt2 is 10-fold higher than that of LdtMt1
(Gupta et al., 2010). These data underscore the importance of
L,D-transpeptidase activity as a chemotherapeutic target.
Structural Comparison with Other L,D-Transpeptidases
The structure determined here shows that the bulk of the ex-
LdtMt2 CD (251–379 aa) has a fold similar to those of the
C-terminal domain of B. subtilis ykuD (Bielnicki et al., 2006) and
the CD of the L,D-transpeptidase of E. faecium Ldtfm (Biarrotte-
Sorin et al., 2006). LdtMt2 shows 23% sequence identity with2012 Elsevier Ltd All rights reserved 2109
-0.050
-0.025
0.000
0.025
0.050
0 50 100 150
Time (min)
μc
al
/s
0 1 2 3 4 5
-0.5
0.0
0.5
Molar Ratio
kc
al
/m
ol
e 
of
 in
je
ct
an
t
His336
Met303
His352
Ser351
Asn356
Tyr318 Ala354 
A B Figure 6. C354A Mutant
(A) ITC of imipenem binding to the C354A mutant.
Upper panel shows titration of the C354 mutant
with imipenem. Lower panel is a plot of the total
heat released as a function of total ligand
concentration for the titration shown in the upper
panel. No heat of binding is detected, only heat of
dilution.
(B) Refined electron density of the C354A mutant
around the mutated residue. Final refinement
2DFo mFc map contoured at 1 s around Ala354
of the mutant. Carbon atoms are colored in cyan,
the rest as in Figure 1.
See Table S1 for the C354A mutant structure
determination statistics.
Structure
Structure of Mtb LdtMt2Ldtfm, mostly concentrated in the CD. Despite having similar
two-domain architectures and CDs, the three enzymes differ
significantly in their N-terminal domains (Figure 8). YkuD shows
a small N-terminal domain with a fold, LysM, that is associated
with cell wall degradation (Bateman andBycroft, 2000). The Ldtfm
stalk domain is a 60-A˚-long cylinder formed by a four a helix
bundle, with each helix of the bundle connected by a small
two-strand antiparallel b sheet (Figure 8A). The relative orienta-
tion of the two domains of Ldtfm is maintained by a long loop
that follows the third a helix of the stalk domain resulting in an
82-A˚-long cylindrical molecule (Figure 8A). In contrast, the orien-
tation of the two domains of ex-LdtMt2 is maintained by direct
interaction of residues of the CTSD with residues of the IgD,
resulting in a maximum dimension of only 60 A˚ (Figure 8A).
The solvent accessibility of the catalytic site is very different
in these three bacterial enzymes: ykuD shows a completely
open site, whereas LdtMt2 and Ldtfm show a site cover by the
b-hairpin flap (Figure 8B). The b-hairpin flap of LdtMt2 is similar
to that of Ldtfm, although it has a seven-residue longer loop LF
that narrows the inner cavity of LdtMt2. The catalytic site of
ykuDshows thegreatest divergenceof the three sites (Figure 8C).
Although these three enzymes preserve a similar arrangement
of the catalytic triad residues, most of the LdtMt2 and Ldtfm cata-
lytic site residues are conserved with only a few changes that
(nevertheless) maintain the overall shape of the site (Figure 8C).
Mtb LdtMt2 Homologs
Comparative modeling of LdtMt2 homologs inMtb predicts local-
ized variations in their IgD and CD that may perturb the IgD-CD
interaction. Loop modifications at the interface between the
IgD and CD, and the loss of CTSD interaction with the IgD
(Figure 3A), could change each enzyme’s overall shape and flex-
ibility. It is worth noting that these homologs are membrane-
associated proteins and have different levels of expression
during different phases of growth (Gupta et al., 2010). Their
different shape and flexibility could reflect the fact that these
enzymes are specialized to target different peptidoglycan layer
constituents, act at different levels in the three-dimensional
peptidoglycan layer (Vollmer and Ho¨ltje, 2004), or form a partic-
ular crosslinking pattern by acting only on stems that present a2110 Structure 20, 2103–2115, December 5, 2012 ª2012 Elsevier Ltd All rights reservedspatial arrangement that is optimum for
a given enzyme. These multiple enzymes
may provide a mechanism for modulatingthe three-dimensional structure of the peptidoglycan layer
during different phases of growth.
Binding of Imipenem to LdtMt2
The shape of the binding isotherm indicates the presence of
equilibrium between bound and unbound species (Figure 5C).
Kinetic experiments using fluorescence and absorption spectro-
photometric techniques to follow the inactivation by imipenem
of two closely related enzymes, Ldtfm (Triboulet et al., 2011)
and LdtMt1 (Dube´e et al., 2012), showed the presence of an
enzyme-inhibitor complex before the irreversible acylation.
Such complex is consistent with the apparent tight binding of
imipenem to LdtMt2 we observed using ITC (KD = 54.8 ±
8.8 nM). The observation of a tight complex enzyme inhibitor
previous to enzyme-irreversible acylation, the one-to-one rela-
tion between inactivated enzyme and consumed inhibitor
(Figures 7A and 7B), and the lack of binding of the inhibitor to
the catalytically inactive C354A mutant suggest that the forma-
tion of a reversible tetrahedral intermediate (see below) is
required for a strong binding of imipenem to LdtMt2.
LdtMt2 Catalytic Mechanism
Biarrotte-Sorin et al. (2006) proposed that in this kind of L,D-
transpeptidase, the two paths to the catalytic cysteine (via
the inner or the outer cavity; Figure 1C) are used one for the
acyl donor and the other for the acyl-acceptor substrates.
However, in this mechanism, the enzyme would need to go
through multiple conformational changes of the flap to accom-
modate entrance of substrates and release of products using
the catalytic site tunnel. The mode of binding of the peptido-
glycan fragment found in the structure of LdtMt2 suggests a
much simpler mechanism, in which the acyl-donor peptido-
glycan stem binds to both cavities through the tunnel (Figures
1C and 4) and remains bound during most of the catalytic
cycle, reducing the need for conformational changes during
the catalytic cycle of the enzyme. We built models of the pepti-
doglycan stem substrates bound to the active site of the
enzyme based on the structure of LdtMt2 and use it to propose
atomic details of the catalytic mechanism of LdtMt2 (Figure 9).
In this model, the catalytic site tunnel and features at either
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Figure 7. Enzymatic Activity of LdtMt2
(A and B) Irreversible inhibition by imipenem. (A) Three selected concentrations of enzyme (10, 35, and 60 mM) reacting with 100 mM of imipenem. (B) Plot of the
concentration of imipenem reacted versus the concentration of enzyme used (10, 20, 35, 40, 50, and 60 mM).
(C) Initial rate experiments of the ex-LdtMt2 b-lactamase activity using nitrocefin as substrate (structural formula is shown). Solid lines are the nonlinear fit of the
initial rate to the Michaelis-Menten equation. Note that pH 7 and 8.5, and 6.5 and 9 overlap. The error bars correspond to the estimated SE of the nonlinear fitting.
(D) Plot of the log of kcat for nitrocefin as a function of pH. See also Table S2.
(E and F) Progress of the reaction of nitrocefin (100 mM) and LdtMt2 (500 nM). (E) Initial phase of the reaction (controlled by binding and acylation rates). (F) Later
phase of the reaction (controlled by deacylation rate). The amount of product (open ring) is monitored by its absorption at 486 nM. Errors bars in (E) represent the
deviation between two measures.
See also Tables S2 and S3.
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Figure 8. Structural Comparison among
L,D-Transpeptidases from B. subtilis,
E. faecium, and Mtb
(A) Side-by-side ribbon diagrams of the crystal
structures of the L,D-transpeptidases: ykuD (PDB
1Y7M) in pink (rmsd of 0.97 A˚ between 104 Ca
atoms aligned with ex-LdtMt2); Ldtfm (PDB 1ZAT) in
cyan (1.0 A˚ rmsd between 116 Ca atoms aligned);
andLdtMt2 in green. In theE. faecium andMtb case,
the regions that apparently fix the domain orien-
tation are colored in dark green. The CDs of the
three enzymes were used to align the structures.
(B) Comparison of the CDs. The catalytic cysteine
residue is depicted in a CPK representation with
carbon atoms purple and sulfur atom yellow.
(C) Catalytic site residues of the three enzymes.
Viewed from the outer cavity, the catalytic site
residues are shown as side chains or main
chains according to their expected function. The
catalytic site triad is labeled with pink letters. The
g-glutamyl-meso-diaminopymelic acid (g-D-Glu-
m-A2pm) is shown only for ldtMt2 in a stick repre-
sentation with magenta-colored carbon atoms.
Noncarbon atoms are colored as in Figure 1. H
bond interactions of the peptidoglycan fragment
with residues of the catalytic site are shown with
dashed lines.
Structure
Structure of Mtb LdtMt2side of the tunnel tightly bind the stem diamino acid (A2pm
3).
At one end of the tunnel, within the inner cavity, Tyr318 and
the carbonyl group of Gly332 recognize the D chiral center of
the diamino acid side chain, making H bonds to its carboxylate
and amide group. The tunnel recognizes the aliphatic portion of
the side chain. At the other end, within the outer cavity, the
L chiral center is surrounded by an ‘‘anion hole’’ formed by
the backbone NH group of residues 352–354 at the C terminus
of loop Lc. In this position, the acyl group of the m-A2pm
3 L
chiral center is within reach of Cys354. These features are
consistent with a nucleophilic attack by this cysteine on the
acyl carbon.2112 Structure 20, 2103–2115, December 5, 2012 ª2012 Elsevier Ltd All rights reservedIn the crystal structure of ex-LdtMt2, the
Sg atom of Cys354 points toward the
inside entrance of the catalytic site,
away from the putative acyl group. Iden-
tical cysteine conformations (c y 73)
have been consistently observed in all
the other crystal structures of ErfK/YbiS/
YhnG domain proteins (Biarrotte-Sorin
et al., 2006; Bielnicki et al., 2006). There-
fore, one can expect that earlier in the
catalytic cycle, the cysteine may adopt
another conformation (c y 58) that
points toward the carbonyl carbon of
the scissile bond. In this conformation,
the SH group would be briefly at 2.9 A˚
from the Nε atom of His336, allowing
deprotonation of the Cys354 SH group
for the nucleophilic attack at the peptide
carbonyl group. The imidazolium cation
of the protonated His336 may then bethe donor for the protonation of the departing D-Ala amide.
His336 and Asn356 make H bonds to this CO group, providing
further recognition of the donor stem L chiral center (Figure 4A).
The pH dependence of the reaction rate shows an increase of
b-lactamase activity compatible with the ionization of a group
with a pKa of around 7.8 (Figure 6D; Table S3). Participation
of the Cys354-thiolate/His336-imidazolium ion pair in the con-
certed acid base catalysis of the acyl transfer is compatible
with this pH optimum.
The rest of the interactions between the LdtMt2 and the bound
peptidoglycan fragment involves the side chain of Asn356, which
coordinates the main-chain NH group and the terminal
AB
Figure 9. Proposed Mechanism of the L,D-
Transpeptidation Reaction and Structural
Model of the Acyl-Acceptor and Donor-
Peptidoglycan Stems Bound to the Outer
Cavity of ex-LdtMt2
(A) Steps 1–6 of the mechanism of (3,3) L,D-
transpeptidation by LdtMt2.
(B) The figure represents step 4 of the mechanism
in (A), after the cleaved D-Ala4 has left and a thio-
ester intermediate is formed between acyl donor
(carbon atoms colored pink) and the enzyme
(cyan). Noncarbon atoms are colored as in Fig-
ure 1. Only the last two residues of the donor stem
and the m-A2pm (light gray) of the acceptor stem
are shown. The peptidoglycan stem of the acyl
acceptor binds to the site with its A2pm3
0 side
chain (D chiral center) near the thioester bond
(marked with an asterisk [*]).Solvent-accessible
surface at the outer cavity is presented. The
surface is colored by electrostatic surface poten-
tial (from blue positive to red negative). The two
substrates of the bisubstrate reaction are shown.
Structure
Structure of Mtb LdtMt2carboxylate of D-Ala4 (D-Ala4 binding site). Trp340 provides
steric constraints to the stem terminus that may explain the pref-
erence of the enzyme for tetrapeptide stems (Lavollay et al.,
2008). Interestingly, in one of the Mtb homologs of LdtMt2,
MT0501, a less bulky methionine residue replaces Trp340
(Figure 3B), suggesting that this enzyme can accommodate
pentapeptides, perhaps broadening its specificity from D-Ala to
noncanonical D-amino acids observed by Cava et al. (2011).
Toward theN terminus of the peptidoglycan stem, the conserved
His352provides aHbond to groups of the isoglutamyl side chain.
In the observed tautomer, forced by theHbond to the carbonyl
of Ser337, His336 has its Nε ready to accept a H+ from Cys354Structure 20, 2103–2115, December 5, 2012 ª(Figure 9A, step 1). The cysteine thiolate
formed by this H+ abstraction attacks
the acyl carbon and forms a tetrahedral
intermediate stabilized by the ‘‘anion
hole’’ and by the just protonated His336
(Figure 9A, step 2). After the intermediate
thioester formation and protonation by
His336, D-Ala4 is released (Figure 9A,
step 3). Then another peptide stem can
enter the catalytic site, also through the
external vestibule, and bind to active
site residues with the side-chain amide
of the A2pm
30 residue (also a D chiral
center and isomorphic to D-Ala4) (Figures
9A and 9B, step 4). His336 is in position to
activate the amine group of the acceptor
stem D chiral center (Figure 9A, step 4).
Nucleophilic attack by this amine group
forms the new peptide bond that cross-
links the two stems with release and
protonation of the cysteine thiolate by
His336 (Figure 9, steps 5 and 6). It is clear
that the last step in the transpeptidation
reaction requires that donor and acceptor
peptidoglycan stems both be at the cata-lytic site for the reaction to occur (Figure 9B). The wide and
shallow entrance of the outer cavity has the required character-
istics to accommodate both peptidoglycans stems (Figure 9B).
Higher-order crosslinked stems are also observed in Mtb,
though with low frequency (3%) (Lavollay et al., 2008), suggest-
ing that already-linked peptidoglycan stems are not precluded
from participating in new crosslinks. Linked stems can dock
in the vestibule with their unreacted D chiral center reaching
the catalytic residues without any conformational change in
the enzyme. The use of the unreacted L chiral center of an
already-crosslinked stem as acyl donor imposes more steric
constraints and most likely involves the opening of the flap. After2012 Elsevier Ltd All rights reserved 2113
Structure
Structure of Mtb LdtMt2formation of the new crosslink, release of the higher-order linked
peptide stems will require opening the flap again.
Conclusions
The crystal structure of the complex of an Mtb L,D-transpepti-
dase with a peptidoglycan fragment reported here provides a
three-dimensional map of the extensive interactions between
the peptidyl stem and LdtMt2, involving residues that are con-
served in all members of thisMtb family of L,D-transpeptidases.
Knowing this map is an important step toward a rational design
of high-affinity drugs engineered to inhibit L,D-transpeptidase
activity.
EXPERIMENTAL PROCEDURES
Protein Preparation, Purification, and Crystallization
A truncated construct of MT2594 (Rv2518c) spanning residues 120–408 (ex-
LdtMt2) was expressed in E. Coli BL21(DE3) strains and in a methionine auxo-
troph strain supplemented with SeMet. Proteins were separated from the
lysates using (Ni)-affinity chromatography (Ni-HisTrap; GE Healthcare). Size
exclusion chromatography was performed using a Sepharose column
(Sepharose 12; GE Healthcare). Native and SeMet-derivatized protein
samples were used in the crystallization trials. Diffraction quality crystals of
all forms used in this study were obtained in 48 hr at 20C with hanging drop
vapor diffusionmethods. Drops of 1ml of protein (20mg/ml) and 1 ml of reservoir
solutionwere equilibrated against a reservoir containing 0.1MHEPES (pH 7.5),
1 M succinic acid, and 1% (w/v) PEG MME 2000, except for SeMet crystals in
which HEPES at pH 7.0 was used. For heavy-atom derivates, crystals were
soaked in 10 ml of reservoir solution containing the heavy-atom compounds
at the desired concentration. In the case of PIP, ex-LdtMt2 crystals were
soaked with 100 mM for 48 hr. See Supplemental Experimental Procedures
for additional details.
Data Collection, Structure Determination, and Refinement
Diffraction data of the PIP derivative, mutant, and BME disulfide adduct and
oxidized forms of the native were collected using an in-house CuKa X-ray
source (FR-E+ SuperBright generator with a Saturn 944+ CCD Detector; Ri-
gaku, The Woodlands, TX, USA). The SeMet-derivative crystal used in the
phase determination was collected on beamline X4A of the National Synchro-
tron Light Source of the Brookhaven National Laboratory (Table 1). X-ray
diffraction experiments were carried out under cryogenic conditions after
transferring the crystal into crystallization solution containing 10% v/v glycerol.
Intensities were indexed and integrated using HKL2000 (HKL Research). Data
were scaled with the CCP4 program suite (Collaborative Computational
Project, Number 4, 1994). Phases were determined using the program au-
toSHARP (Vonrhein et al., 2007). Refinement was carried out using REFMAC5
(Murshudov et al., 2011), and rebuilding was done with Coot (Emsley and
Cowtan, 2004).
Calorimetric Studies
ITC experiments were performed using a high-precision VP-ITC titration
calorimeter system (MicroCal Software, Northampton, MA, USA). The buffer
of the protein samples was replaced by 20 mM HEPES, 300 mM NaCl
(pH 7.5) using a desalting column (HiTrap G-25; GE Healthcare). Inhibitors
and substrates used in these experiments were dissolved in the same buffer.
ITC experiments using PBS and PIPES showed similar DH values, indicating
that no H+s were released or bound during the reaction. Titration experiments
consisted of the addition of 25 injections of 10 ml of concentrated inhibitor into
the protein solution contained in the cell (1.38 ml) with 300–450 s equilibration
between injections. Data were analyzed with Origin 5.0 software (MicroCal)
with a single-site model. Imipenem monohydrate and meropenem were
purchased from Sigma-Aldrich.
Enzyme Kinetics
Initial rate measurements were used to determine the steady-state kinetic
parameters of the b-lactamase activity against nitrocefin—3-(2,4-Dinitros-2114 Structure 20, 2103–2115, December 5, 2012 ª2012 Elsevier Ltdtyryl)-(6R, 7R)-7-(2-thienylacetamido)-ceph-3-em-4-carboxylic acid, EMD
(Figure 7D)—a chromogenic b-lactam. The b-lactamase activity was
measured by following the absorbance of the product produced by opening
the lactam ring at 486 nm using a molar extinction coefficient of 20,500
M1cm1 (O’Callaghan et al., 1972) in metal-free buffer of 20 mM HEPES
(pH 7.5) and 300 mM NaCl. Nitrocefin was added at concentrations ranging
from 12.5 to 200 mM. The kinetic parameters, KM, and kcat were fitted by
a nonlinear least-squares fit of Michaelis-Menten equation to the initial rate
measurements.
Enzyme acylation by imipenem was measured by quantifying the amount of
reacted imipenem at a given time, following the formation of the open penem
ring product by monitoring the absorbance at 299 nm. The decrease in absor-
bance values was converted into concentration units using the difference
between molar extinction coefficients of the open and closed penem ring
of 7,100 M1cm1 (Triboulet et al., 2011).
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